cagrilintide vs tirzepatide CagriSema Tirzepatide: Research Compared cagrilintide vs retatrutide vs tirzepatide

Of those, there were eight reports of blindness, two reports of blindness unilateral, eight reports of visual impairment, and 13 reports of optic ischaemic neuropathy

Imbernon M, Saponaro C, Helms HCC, Duquenne M, Fernandois D, Deligia E, et al

The SURMOUNT-5 trial showed participants lost an average of 20.2 percent of their body weight over 72 weeks, and that kind of transformation requires eating significantly less food for an extended period

On 8 November 2023, Tirzepatide, branded as Zepbound in the US, received FDA approval as the first dual-target agonist for the treatment of obesity, further highlighting its potential in medical treatment options